Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Shah, Nirav N, Wang, Michael, Roeker, Lindsey E, Patel, Krish, Woyach, Jennifer A, Wierda, William G, Ujjani, Chaitra S, Eyre, Toby A, Zinzani, Pier Luigi, Alencar, Alvaro J, Ghia, Paolo, Lamanna, Nicole, Hoffmann, Marc S, Patel, Manish R, Flinn, Ian, Gerson, James N, Ma, Shuo, Coombs, Catherine C, Cheah, Chan Y, Lech-Maranda, Ewa, Fakhri, Bita, Kim, Won Seog, Barve, Minal A, Cohen, Jonathon B, Jurczak, Wojciech, Munir, Talha, Thompson, Meghan C, Tsai, Donald E, Bao, Katherine, Cangemi, Nicholas A, Kherani, Jennifer F, Walgren, Richard A, Han, Hongmei, Ruppert, Amy S, Brown, Jennifer R
Published in Haematologica (Roma) (03.10.2024)
Published in Haematologica (Roma) (03.10.2024)
Get full text
Journal Article
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Ou, Sai-Hong Ignatius, Jänne, Pasi A., Leal, Ticiana A., Rybkin, Igor I., Sabari, Joshua K., Barve, Minal A., Bazhenova, Lyudmila, Johnson, Melissa L., Velastegui, Karen L., Cilliers, Cornelius, Christensen, James G., Yan, Xiaohong, Chao, Richard C., Papadopoulos, Kyriakos P.
Published in Journal of clinical oncology (10.08.2022)
Published in Journal of clinical oncology (10.08.2022)
Get full text
Journal Article
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rocconi, Rodney P, Grosen, Elizabeth A, Ghamande, Sharad A, Chan, John K, Barve, Minal A, Oh, Jonathan, Tewari, Devansu, Morris, Peter C, Stevens, Erin E, Bottsford-Miller, Justin N, Tang, Min, Aaron, Phylicia, Stanbery, Laura, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Manning, Luisa, Nemunaitis, John, Shanahan, David, Slomovitz, Brian M, Herzog, Thomas J, Monk, Bradley J, Coleman, Robert L
Published in The lancet oncology (01.12.2020)
Published in The lancet oncology (01.12.2020)
Get full text
Journal Article
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors
Conley, Anthony P., Roland, Christina L., Bessudo, Alberto, Gastman, Brian R., Villaflor, Victoria M., Larson, Christopher, Reid, Tony R., Caroen, Scott, Oronsky, Bryan, Stirn, Meaghan, Williams, Jeannie, Burbano, Erica, Coyle, Angelique, Barve, Minal A., Wagle, Naveed, Abrouk, Nacer, Kesari, Santosh
Published in Cancer gene therapy (01.04.2024)
Published in Cancer gene therapy (01.04.2024)
Get full text
Journal Article
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
Ou, Sai-Hong Ignatius, Jänne, Pasi A, Leal, Ticiana A, Rybkin, Igor I, Sabari, Joshua K, Barve, Minal A, Bazhenova, Lyudmila, Johnson, Melissa L, Velastegui, Karen L, Cilliers, Cornelius, Christensen, James G, Yan, Xiaohong, Chao, Richard C, Papadopoulos, Kyriakos P
Published in Journal of clinical oncology (10.08.2022)
Published in Journal of clinical oncology (10.08.2022)
Get full text
Journal Article
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors
Kesari, Santosh, Bessudo, Alberto, Gastman, Brian R, Conley, Anthony P, Villaflor, Victoria M, Nabell, Lisle M, Madere, DeLisa, Chacon, Emma, Spencer, Christina, Li, Li, Larson, Christopher, Reid, Tony, Caroen, Scott, Oronsky, Bryan, Stirn, Meaghan, Williams, Jeannie, Barve, Minal A
Published in Future oncology (London, England) (01.09.2022)
Published in Future oncology (London, England) (01.09.2022)
Get full text
Journal Article
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results
Coward, Jermaine I, Barve, Minal A, Kichenadasse, Ganessan, Moore, Kathleen N, Harnett, Paul R, Berg, Daniel, Garner, James S, Dizon, Don S
Published in Cancers (26.06.2021)
Published in Cancers (26.06.2021)
Get full text
Journal Article
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Cohen, Jonathon B, Shah, Nirav N, Alencar, Alvaro J, Gerson, James N, Patel, Manish R, Fakhri, Bita, Jurczak, Wojciech, Tan, Xuan Ni, Lewis, Katharine L, Fenske, Timothy, Coombs, Catherine C, Flinn, Ian W, Lewis, David J, Gouill, Steven Le, Palomba, M Lia, Woyach, Jennifer A, Pagel, John M, Lamanna, Nicole, Barve, Minal A, Ghia, Paolo, Eyre, Toby A, Zinzani, Pier Luigi, Ujjani, Chaitra S, Koh, Youngil, Izutsu, Koji, Lech-Maranda, Ewa, Tam, Constantine S, Sundaram, Suchitra, Yin, Ming, Nair, Binoj, Tsai, Donald E, Balbas, Minna, Mato, Anthony R, Cheah, Chan Y, Wang, Michael L
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
Blau, Sibel, Peguero, Julio Antonio, Moore, Halle C F, Anderson, Ian Churchill, Barve, Minal A, Cherian, Mathew Amprayil, Elkhanany, Ahmed, O'Sullivan, Ciara Catherine, Moreno-Aspitia, Alvaro, Plourde, Paul, Gleich, Lyon L, Riesen, Kendra, Ezzati, Ross, Degele, Meghan, Shulman, Megan, Stempf, Stephanie Dobson, Sachse, Laura, Iyer, Amrita A, Damodaran, Senthil, Cooney, Matthew M
Published in JCO clinical cancer informatics (01.06.2023)
Published in JCO clinical cancer informatics (01.06.2023)
Get more information
Journal Article
P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
Scarfò, Lydia, Patel, Manish R., Eyre, Toby A., Jurczak, Wojciech, Lewis, David, Gastinne, Thomas, MA, Shuo, Cohen, Jonathon B., Patel, Krish, Brown, Jennifer R., Munir, Talha, Lech‐Maranda, Ewa, Hoffmann, Marc S., Ujjani, Chaitra S., Fakhri, Bita, Wang, Michael, Izutsu, Koji, Nagai, Hirokazu, Tam, Constantine S., Seymour, John F., Rhodes, Joanna, Vose, Julie, Mckinney, Matthew, Gerson, James N., Barve, Minal A., Kuss, Bryone, Koh, Youngil, Gao, Wei, Ruppert, Amy S., Walgren, Richard A., Tsai, Donald E., Nair, Binoj, Bao, Katherine, Mato, Anthony R., Cheah, Chan Y., Lia Palomba, M
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
Holmes, Frankie Ann, Hellerstedt, Beth A., Pippen, John E., Vukelja, Svetislava J., Collea, Rufus P., Kocs, Darren M., Blum, Joanne L., McIntyre, Kristi J., Barve, Minal A., Brooks, Barry D., Osborne, Cynthia R., Wang, Yunfei, Asmar, Lina, O'Shaughnessy, Joyce
Published in Cancer medicine (Malden, MA) (01.06.2018)
Published in Cancer medicine (Malden, MA) (01.06.2018)
Get full text
Journal Article
A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2
Pelster, Meredith, Perez, Cesar Augusto, Chandana, Sreenivasa R, Uboha, Nataliya Volodymyrivna, Swami, Ashwin, McDonald, Holly, Srivastava, Jaya, Barve, Minal A.
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations
Heymach, John, Opdam, Frans, Barve, Minal A., Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yamamoto, Noboru
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, Anthony R, Shah, Nirav N, Jurczak, Wojciech, Cheah, Chan Y, Pagel, John M, Woyach, Jennifer A, Fakhri, Bita, Eyre, Toby A, Lamanna, Nicole, Patel, Manish R, Alencar, Alvaro, Lech-Maranda, Ewa, Wierda, William G, Coombs, Catherine C, Gerson, James N, Ghia, Paolo, Le Gouill, Steven, Lewis, David John, Sundaram, Suchitra, Cohen, Jonathon B, Flinn, Ian W, Tam, Constantine S, Barve, Minal A, Kuss, Bryone, Taylor, Justin, Abdel-Wahab, Omar, Schuster, Stephen J, Palomba, M Lia, Lewis, Katharine L, Roeker, Lindsey E, Davids, Matthew S, Tan, Xuan Ni, Fenske, Timothy S, Wallin, Johan, Tsai, Donald E, Ku, Nora C, Zhu, Edward, Chen, Jessica, Yin, Ming, Nair, Binoj, Ebata, Kevin, Marella, Narasimha, Brown, Jennifer R, Wang, Michael
Published in The Lancet (British edition) (06.03.2021)
Published in The Lancet (British edition) (06.03.2021)
Get full text
Journal Article
Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study
Niu, Jiaxin, Barve, Minal A., Spira, Alexander I., Edenfield, William Jeffery, Pang, Weijia, Fu, Wenmin, Lu, Yingxin, McKean, Meredith
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)
Winer, Ira Seth, Barve, Minal A., Shah, Satish, Sharma, Manish, Marsolais, Christian, Demeule, Michel, Daigle, Kathya, Douglas, Lynn Marie, Meric-Bernstam, Funda
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
Heymach, John, Opdam, Frans, Barve, Minal A., Tu, Hai-Yan, Wu, Yi-Long, Berz, David, Rohrbacher, Maren, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Yamamoto, Noboru
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors
Shapiro, Geoffrey, Barve, Minal A., Bhave, Manali A., Subbiah, Vivek, Uttamsingh, Shailaja, Sharma, Keerti, Andrianova, Lana, Patnaik, Amita
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers
Gutierrez, Martin, Balmanoukian, Ani Sarkis, Shields, Anthony F., Johnson, Melissa Lynne, Ulahannan, Susanna Varkey, Barve, Minal A., Ioannidis, Sonia, Zhou, Feng, Bourayou, Nawel, Hamid, Omid
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data
Heymach, John, Opdam, Frans, Barve, Minal A., Tu, Hai-Yan, Wu, Yi-Long, Berz, David, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Yamamoto, Noboru
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article